Mittlmeier, L. M.
Unterrainer, M.
Rodler, S.
Todica, A.
Albert, N. L.
Burgard, C.
Cyran, C. C.
Kunz, W. G.
Ricke, J.
Bartenstein, P.
Stief, C. G.
Ilhan, H.
Staehler, M.
Funding for this research was provided by:
Projekt DEAL
Article History
Received: 11 September 2020
Accepted: 13 December 2020
First Online: 28 December 2020
Compliance with ethical standards
:
: M.S.: Consultant: Pfizer, GlaxoSmithKline, Novartis, Bayer, Roche, Aveo, EUSAPharm, Astellas, Ipsen, Exelixis, Pelloton, EISAI, BMS, MSD; honoraria: Pfizer, GlaxoSmithKline, AVEO, Novartis, Bayer, EUSAPharm, Astellas, Ipsen, Exelixis, Pelloton, EISAI, BMS, MSD; research funding: Pfizer, GlaxoSmithKline, AVEO, BMS, Novartis, Bayer, Roche/Genentech, Immatics, Wilex, Ipsen, Exelixis, EISAI. H.I.: Honoraria: Bayer, Sirtex Medical, Novartis. N.L.A: member of the EANM brain imaging committee. W.G.K.: member of the Imaging Group of the EORTC. All other authors declare that they have no relationships or interests that could have direct or potential influence or impart bias on the work.
: The analysis was authorized by the local ethics committee in accordance with the ICH Guideline for Good Clinical Practice (GCP) and the declaration of Helsinki.
: All patients gave written consent to undergo PET/CT scans as part of the clinical routine. The radiopharmaceutical was used on an individual patient basis according to German Pharmaceuticals Act ยง13(2b).